Gme, this is what I spoke with you about. Still can't figure it out. To me, it sounds like they don't have to report whether they bought or sold in November or they don't want us to know that maybe the bought less. I honestly do not know how to read it. I guess we will find out sooner than later. GLTA
All the recent CT (Confidential Treatment) filing pertains is the granting of CT to words that were struck out in exhibits that were a part of the Sch. 13D filed by Celgene back on Nov. 27th. Exhibit 2 is a copy of the License, Marketing and Development Agreement between CCT and Alliqua the and Exhibit 3 is a copy of the Supply Agreement between the two companies.
When those Exhibits were filed along with the 13D back in November, certain words in each of the two agreements noted above were replaced with **** (asterisks) and Celgene applied to the SEC for a CT order to keep the removed from being made public at this time because they contain confidential/sensitive/proprietary commercial information about their business. The SEC has now granted confidential treatment (CT) and those stricken words will not be made public information until 11/14/2018.
Standard stuff to apply to have certain information contained in Licensing Agreements between two companies to be withheld from being made public to your competitors, etc.